GleamWall
中文EN

LRMR Larimar Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1374690 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-18.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-129.8%
ROA-95.2%
ROIC (approx.)-348.7%
Asset turnover—

Leverage & solvency

Liabilities / assets27.8%
Debt / equity0.00x
Current ratio3.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio1.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$25.93M$28.00M$25.03M$59.37M$44.93M$23.37M$26.55M$26.74M
SG&A expense$6.54M$6.35M$6.09M$4.64M$4.57M$4.42M$4.64M$4.55M
Operating income-$32.46M-$34.35M-$31.12M-$64.02M-$49.50M-$27.79M-$31.19M-$31.29M
Income tax———$0$0$0—$0
Net income-$31.14M-$32.78M-$29.61M-$62.50M-$47.71M-$26.18M-$29.28M-$28.82M
EBITDA-$32.41M-$34.29M-$31.05M-$63.93M-$49.41M-$27.70M-$31.10M-$31.22M
EPS (basic)————-0.61-0.41-0.46—
EPS (diluted)————-0.61-0.41-0.46—
Weighted avg. shares (diluted)————78.32M64.03M63.96M—
Balance sheet
Cash & equivalents$76.99M$92.69M$177.91M$85.41M$90.14M$20.59M$21.13M$33.22M
Short-term investments$51.67M$63.58M$22.47M$51.44M$85.30M$117.94M$136.40M$150.24M
Current assets$136.15M$160.67M$204.98M$142.02M$183.22M$145.56M$165.49M$195.30M
PP&E, net$597,000$639,000$558,000$622,000$709,000$797,000$855,000$881,000
Total assets$140.50M$165.30M$208.51M$145.84M$187.35M$149.99M$170.18M$200.22M
Current liabilities$35.65M$34.17M$47.76M$64.80M$45.12M$26.65M$22.13M$24.36M
Total liabilities$39.04M$37.92M$50.48M$67.76M$48.31M$30.13M$25.90M$28.41M
Shareholders' equity$101.47M$127.38M$158.03M$78.08M$139.04M$119.85M$144.27M$171.81M
Shares outstanding104.63M103.88M103.88M83.09M85.59M64.03M64.03M63.82M
Cash flow statement
Operating cash flow-$31.19M-$44.03M-$44.61M-$38.53M-$28.75M-$19.38M-$26.54M-$21.82M
Capital expenditure$28,000——$0$23,000$19,000$49,000$179,000
Free cash flow-$31.21M——-$38.53M-$28.78M-$19.40M-$26.59M-$21.99M
Investing cash flow$12.43M-$40.91M$29.00M$34.00M$33.02M$18.84M$14.45M$19.20M
Financing cash flow$3.05M-$435,000$108.11M-$201,000$65.29M——$36,000
Depreciation & amortization$57,000$62,000$64,000$87,000$88,000$87,000$88,000$77,000
Stock-based compensation$2.17M$2.15M$1.98M$1.56M$1.78M$1.83M$1.83M$2.41M

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.